Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the...
Gainers:Singular Genomics Systems (OMIC) +5%. Sonos (SONO) +5%. Fulton Financial Corporation (FULT) +5%. CytomX Therapeutics (CTMX) +5%. Walgreens Boots Alliance (WBA) +4%. Losers: Netflix (NFLX) -26%. LifeStance Health Group (LFST) -8%. INMODE (INMD) -8%. Rok...
Gainers: Super Micro Computer (SMCI) +14%. Luminar Technologies (LAZR) +5%. Veeco Instruments (VECO) +5%. CytomX Therapeutics (CTMX) +5%. Syndax Pharmaceuticals (SNDX) +5%. Losers: NETGEAR (NTGR) -11%. Lakeland Industries (LAKE) -9%. ACADIA Pharmaceuticals ...
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current t...
CytomX Therapeutics Inc. (NASDAQ:CTMX) traded today at a new 52-week high of $37.00. So far today approximately 32.2 million shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, CytomX Therapeutics Inc. has traded in a range of $2...
Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) traded today at $37.00, eclipsing its 52-week high. Approximately 32.1 million shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares. CytomX Therapeutics Inc. (NASDAQ:CTMX) has potential upside of 1...
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th, 2022. ...
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine ...
The following slide deck was published by CytomX Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: CytomX Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
CytomX Therapeutics (CTMX +16.2%) rose following its FY21 results, which missed on analysts' estimates. Q4 total revenues rose 20.2% Y/Y to $19.7M. The increase in Q4 revenue was largely related to the CD71 collaboration with AbbVie. FY21 revenue declined to $69.57M, compared to $100.36M...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...